Why is this medication prescribed?

Daratumumab is a medication primarily prescribed for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is often used in combination with other medications for patients who have received at least one prior therapy.

Daratumumab works by targeting a protein called CD38, which is found in high levels on the surface of myeloma cells. By binding to CD38, daratumumab helps the body’s immune system attack and kill the cancer cells.

How should this medicine be used?

Daratumumab injection is typically administered intravenously (IV) by a healthcare professional in a hospital, clinic, or infusion center. The dosage and schedule of daratumumab administration can vary based on factors such as the patient’s medical condition, overall health, and response to treatment. Here are some general guidelines on how daratumumab injection is used:

• Preparation: Before administering daratumumab, healthcare providers will assess the patient’s medical history, perform necessary tests, and ensure that the patient is suitable for treatment. The medication is typically stored refrigerated and should be brought to room temperature before administration, following the manufacturer’s instructions.
• Infusion: Daratumumab is administered as an intravenous infusion over a specified period, usually several hours. The exact duration of the infusion may vary depending on factors such as the patient’s tolerance and any potential infusion-related reactions. Healthcare providers will closely monitor the patient during the infusion for any signs of adverse reactions.
• Dosage: The dosage of daratumumab can vary based on factors such as the patient’s weight, medical history, and the specific treatment regimen prescribed by the healthcare provider. Typically, daratumumab is administered weekly for the first two cycles, then every two weeks for four cycles, followed by monthly maintenance doses. However, dosing may be adjusted based on the individual patient’s response and tolerability.
• Pre-medication: Patients may receive pre-medications such as antihistamines, corticosteroids, and/or acetaminophen before daratumumab infusion to help reduce the risk of infusion-related reactions.
• Monitoring: Throughout the infusion and following administration, healthcare providers will closely monitor the patient for any signs of adverse reactions, including infusion-related reactions, allergic reactions, and infections. Vital signs, such as blood pressure, heart rate, and temperature, may be monitored regularly during and after the infusion.
• Follow-up: After daratumumab infusion, patients may require periodic follow-up appointments with their healthcare provider to assess their response to treatment, monitor for any side effects, and adjust the treatment plan as needed.

It’s essential for patients to follow their healthcare provider’s instructions regarding daratumumab administration carefully and to report any concerning symptoms or side effects promptly. Additionally, patients should inform their healthcare provider about any medications, supplements, or herbal products they are taking, as these may interact with daratumumab or affect its effectiveness.

Other uses for this medicine

Daratumumab is primarily used for the treatment of multiple myeloma, but it may also be used for other conditions off-label or in clinical trials. Some potential off-label uses or investigational uses may include other types of cancers where CD38 is expressed, such as certain lymphomas or leukemias. However, it’s essential to note that the use of daratumumab for these conditions would require careful consideration and evaluation by a healthcare professional.

What special precautions should I follow?

Regarding special precautions for daratumumab injection, here are some important points to keep in mind:

• Allergic Reactions: Patients should be monitored for signs of allergic reactions during and after daratumumab infusion. These reactions may include fever, chills, rash, difficulty breathing, or swelling of the face or throat. In severe cases, allergic reactions can be life-threatening and require immediate medical attention.
• Infusion Reactions: Infusion-related reactions, such as fever, chills, nausea, vomiting, headache, or low blood pressure, are common with daratumumab. Healthcare providers may administer medications before the infusion to help prevent or minimize these reactions.
• Infections: Daratumumab can suppress the immune system, increasing the risk of infections. Patients should be monitored for signs of infection, and healthcare providers may recommend prophylactic antibiotics or antiviral medications.
• Interference with Blood Testing: Daratumumab can interfere with certain blood tests, such as blood typing and cross-matching for blood transfusions. This interference may persist for several months after treatment discontinuation, potentially leading to incorrect results. Patients should inform healthcare providers about daratumumab treatment before undergoing blood tests.
• Pregnancy and Breastfeeding: There is limited data on the use of daratumumab in pregnant women, and it may pose risks to the fetus. Women of childbearing potential should use effective contraception during daratumumab treatment and for at least three months after the last dose. It is not recommended to breastfeed while receiving daratumumab treatment.
• Liver and Kidney Function: Daratumumab can affect liver and kidney function. Patients should undergo regular monitoring of liver and kidney function tests during treatment, and dosage adjustments may be necessary in patients with impaired liver or kidney function.
• Other Medications: Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking, as some medications may interact with daratumumab, potentially affecting its effectiveness or increasing the risk of side effects.

It’s crucial for patients to discuss any questions or concerns about daratumumab treatment with their healthcare provider to ensure safe and effective use.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with daratumumab injection. However, maintaining a balanced and healthy diet can support overall well-being during treatment. Stay hydrated and eat a variety of nutritious foods to help support your immune system and overall health.

What should I do if I forget a dose?

If you miss a dose of daratumumab, contact your healthcare provider as soon as possible to discuss the next steps. They will provide guidance on whether the missed dose needs to be rescheduled or adjusted based on your treatment plan and individual circumstances. It’s essential not to administer extra doses or make changes to your treatment regimen without consulting your healthcare provider first. Follow their instructions carefully to ensure the safe and effective continuation of your treatment.

What side effects can this medication cause?

Daratumumab injection, like many medications, can cause side effects, although not everyone experiences them. Common side effects of daratumumab may include:

• Infusion-related reactions: These reactions can occur during or shortly after the infusion and may include symptoms such as fever, chills, nausea, vomiting, headache, fatigue, dizziness, or low blood pressure. Pre-medications may be given to help reduce the risk of infusion-related reactions.
• Infections: Daratumumab can weaken the immune system, increasing the risk of infections. Common infections include upper respiratory tract infections, urinary tract infections, pneumonia, and herpes zoster (shingles).
• Fatigue: Feeling tired or fatigued is a common side effect of daratumumab treatment.
• Nausea and vomiting: Some patients may experience nausea and vomiting as side effects of daratumumab.
• Diarrhea or constipation: Gastrointestinal symptoms like diarrhea or constipation may occur in some individuals.
• Back pain: Back pain is another reported side effect of daratumumab.
• Peripheral neuropathy: This condition involves numbness, tingling, or pain in the hands and feet.
• Low blood cell counts: Daratumumab may cause low levels of red blood cells (anemia), white blood cells (neutropenia), and platelets (thrombocytopenia), which can increase the risk of infections and bleeding.
• Allergic reactions: Rarely, daratumumab can cause severe allergic reactions, which may include rash, itching, difficulty breathing, or swelling of the face, lips, or throat.
• Liver and kidney problems: Some patients may experience changes in liver or kidney function tests while receiving daratumumab.

It’s essential to promptly report any new or worsening symptoms to your healthcare provider while undergoing daratumumab treatment. They can provide guidance on managing side effects and may adjust your treatment regimen if necessary. Additionally, healthcare providers may monitor your health closely during treatment to identify and manage any potential side effects.

What should I know about storage and disposal of this medication?

Here’s what you should know about the storage and disposal of Daratumumab Injection:

• Storage: Daratumumab Injection should be stored in its original packaging in the refrigerator at a temperature of 2°C to 8°C (36°F to 46°F). Do not freeze or shake the medication. Keep it away from light.
• Handling: Daratumumab Injection should be handled with care. Avoid dropping or damaging the vial or syringe. Follow proper aseptic technique when preparing and administering the medication.
• Expiration Date: Check the expiration date on the packaging of Daratumumab Injection. Do not use the medication if it has expired.
• Disposal: Dispose of unused or expired Daratumumab Injection according to local regulations. Your healthcare provider or pharmacist can provide guidance on proper disposal methods.

In case of emergency/overdose

• Seek Medical Attention: If you suspect an overdose or experience severe adverse reactions after receiving Daratumumab Injection, seek immediate medical assistance. Call your local emergency services or go to the nearest emergency room.
• Symptom Management: Follow any instructions provided by medical professionals for managing symptoms of overdose or adverse reactions. This may include supportive care, such as intravenous fluids, medications to treat symptoms, or close monitoring of vital signs.
• Reporting: Report the overdose or adverse reactions to your healthcare provider, who can document the incident and provide further guidance on your treatment plan.

What other information should I know?

• Follow-up Appointments: Attend all scheduled follow-up appointments with your healthcare provider during and after Daratumumab treatment. These visits allow for monitoring of your response to treatment, assessment of side effects, and adjustments to your treatment plan if needed.
• Medication Interactions: Inform your healthcare provider about all medications, supplements, and herbal products you are taking, as they may interact with Daratumumab Injection. Your healthcare provider can advise you on potential interactions and adjust your treatment regimen accordingly.
• Pregnancy and Breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits of Daratumumab Injection with your healthcare provider. Daratumumab may cause harm to the fetus or nursing infant, so appropriate precautions should be taken.
• Patient Support: Take advantage of available patient support resources, such as educational materials, support groups, or counseling services, to help you navigate your Daratumumab treatment journey and manage any challenges or concerns that arise. Your healthcare provider or the pharmaceutical company may offer such resources.

By understanding and following these guidelines, you can safely and effectively use Daratumumab Injection as part of your treatment plan. If you have any questions or concerns, don’t hesitate to discuss them with your healthcare provider.